China Resources Pharmaceutical Group Limited (SEHK: 03320), operating under the brand China Resources Pharma, has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings, recorded a revenue of RMB 135.345 billion for the six months ending June 30, 2026.

This figure represents a 1.93% year-on-year increase in revenue for the subsidiary. Meanwhile, the net profit attributable to the parent company's shareholders reached RMB 1.815 billion, reflecting a growth of 3.13% compared to the same period last year.

The company's announcement confirms that the subsidiary's operational performance for the period met expectations, driven by steady progress across its core business segments.

No other financial details were disclosed in the statement, which focuses solely on the key results from the subsidiary's first-half performance.